Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 21

Trial Status

Completed1

Role Distribution

Principal Investigator1
PI Rate100%

Activity Timeline

Clinical Trials (1)

NCT02834364Phase 2Completed
BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)
Patients With BRAFV600 E or BRAFV600K MutationRelapsed or Refractory Multiple Myeloma
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Affiliations

Medizinische Klinik V, University Hospital Heidelberg

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Yang Xiao, MD

Shenzhen Nanshan District Shekou People's Hospital

Related
1 trials

Shared therapeutic areas:

Relapsed or Refractory Multiple Myeloma
Similarity Score15%

Gang An

Institute of Hematology & Blood Diseases Hospital Ethics Committee

Related
1 trials

Shared therapeutic areas:

Relapsed or Refractory Multiple Myeloma
Similarity Score15%

Jin Lu, PhD

Peking University People's Hospital

Related
2 trials

Shared therapeutic areas:

Relapsed or Refractory Multiple Myeloma
Similarity Score15%

Sven Gogov, MD

Incyte Corporation

Related
3 trials

Shared therapeutic areas:

Relapsed or Refractory Multiple Myeloma
Similarity Score15%

Ravi Vij, M.D.

Washington Universtiy in St. Louis

Related
1 trials

Shared therapeutic areas:

Relapsed or Refractory Multiple Myeloma
Similarity Score15%

Martin Kaiser

Institute of Cancer Research, United Kingdom

Related
1 trials

Shared therapeutic areas:

Relapsed or Refractory Multiple Myeloma
Similarity Score15%

Jianmin luo, PhD&MD

The Second Hospital of Hebei Medical University

Related
4 trials

Shared therapeutic areas:

Relapsed or Refractory Multiple Myeloma
Similarity Score15%

Amitabha Mazumder, MD

NYU Langone Health

Related
2 trials

Shared therapeutic areas:

Relapsed or Refractory Multiple Myeloma
Similarity Score15%

Lugui Qiu

Chinese Academy of Medical Sciences & Peking Union Medical College

Related
1 trials

Shared therapeutic areas:

Relapsed or Refractory Multiple Myeloma
Similarity Score15%

Qing Zhang, Doctoral

Guangdong Second Provincial General Hospital

Related
2 trials

Shared therapeutic areas:

Relapsed or Refractory Multiple Myeloma
Similarity Score15%

Publications (0)

No publications found for this investigator.

Clinical Trials (1)

Showing 1 of 1 trials

NCT02834364Phase 2PrincipalInvestigator

BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)

Patients With BRAFV600 E or BRAFV600K MutationRelapsed or Refractory Multiple Myeloma
Completed

All 1 trials loaded